Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.
Dávila J, González-Calle V, Escalante F, Cerdá S, Puig N, García-Sanz R, Bárez A, Montes C, López R, Alonso JM, Aguilar C, García-Mateo A, Labrador J, Aguilera C, García-Coca A, Hernández R, Mateos MV, Ocio EM. Dávila J, et al. Among authors: lopez r. Br J Haematol. 2022 Jul;198(2):278-287. doi: 10.1111/bjh.18182. Epub 2022 Apr 5. Br J Haematol. 2022. PMID: 35383901
Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez ML, Escribano L, Bárez A, Moro MJ, Hernández J, Aguilera C, Cuello R, García-Frade J, López R, Portero J, Orfao A. San Miguel JF, et al. Among authors: lopez r. Semin Oncol. 2003 Apr;30(2):187-95. doi: 10.1053/sonc.2003.50074. Semin Oncol. 2003. PMID: 12720134
Bone remodelation markers are useful in the management of monoclonal gammopathies.
Hernández JM, Suquía B, Queizan JA, Fisac RM, Sanchez JJ, Fernández-Calvo FJ, García-Sanz R, Olivier C, Bárez A, Calmuntia MJ, García-Frade J, Portero JA, López R, Aguilera C, Navajo JA, San-Miguel JF. Hernández JM, et al. Among authors: lopez r. Hematol J. 2004;5(6):480-8. doi: 10.1038/sj.thj.6200564. Hematol J. 2004. PMID: 15570289 Clinical Trial.
Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
Armellini A, Sarasquete ME, García-Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfão A, Gutiérrez NC, González M, San Miguel JF. Armellini A, et al. Among authors: lopez r. Br J Haematol. 2008 Apr;141(2):212-5. doi: 10.1111/j.1365-2141.2007.06956.x. Br J Haematol. 2008. PMID: 18353163 Free article. Clinical Trial.
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Martínez-López J, et al. Blood. 2015 Aug 13;126(7):858-62. doi: 10.1182/blood-2015-04-638742. Epub 2015 Jun 18. Blood. 2015. PMID: 26089396 Free PMC article. Clinical Trial.
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV. González-Calle V, et al. Among authors: lopez r. Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2. Leukemia. 2016. PMID: 27133826
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V, Cerdá S, Labrador J, Sobejano E, González-Mena B, Aguilera C, Ocio EM, Vidriales MB, Puig N, Gutiérrez NC, García-Sanz R, Alonso JM, López R, Aguilar C, de Coca AG, Hernández R, Hernández JM, Escalante F, Mateos MV. González-Calle V, et al. Among authors: lopez r. Haematologica. 2017 May;102(5):922-931. doi: 10.3324/haematol.2016.158345. Epub 2017 Jan 25. Haematologica. 2017. PMID: 28126960 Free PMC article.
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
García-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, López R, Grande-García C, Alegre A, Vargas-Pabón M, Gutiérrez ON, Rodríguez JA, San Miguel JF. García-Sanz R, et al. Among authors: lopez r. Leukemia. 2004 Apr;18(4):856-63. doi: 10.1038/sj.leu.2403322. Leukemia. 2004. PMID: 14973508 Clinical Trial.
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.
Bouza E, Martin M, Alés JE, Aragonés N, Barragán B, de la Cámara R, Del Pozo JL, García-Gutiérrez V, García-Sanz R, Gracia D, Guillem V, Jiménez-Yuste V, Martin-Delgado MC, Martínez J, López R, Rodríguez-Lescure A, Ruiz Galiana J, Sureda AM, Tejerina-Picado F, Trilla A, Zapatero A, Palomo E, San-Miguel J. Bouza E, et al. Among authors: lopez r. Rev Esp Quimioter. 2023 Feb;36(1):1-25. doi: 10.37201/req/087.2022. Epub 2022 Nov 2. Rev Esp Quimioter. 2023. PMID: 36322133 Free PMC article. Review.
3,780 results